Looking beyond the search for a malaria vaccine, one team of researchers is testing whether a vaccine made of mosquito spit proteins can invoke an immune response, which could in turn protect against all mosquito-borne pathogens.
The results from a Phase I trial showed a form of the vaccine was safe and triggered an antibody response in recipients.
This study tested for immune response to mosquito spit proteins but it did not involve pathogens, according to Reuters. Therefore, additional trials are needed to determine the effect of the mosquito spit vaccine against pathogens.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).